About: http://data.cimple.eu/news-article/4169d04936af92067df49d300e3f5ba2fe61a93b9207351e6ebf9362

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/4169d04936af92067df49d300e3f5ba2fe61a93b9207351e6ebf9362 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The coronavirus vaccine being developed by Sanofi won't need to be super-cooled and a normal refrigerator will suffice, the Paris-based drugmaker's France chief Olivier Bogillot said Sunday. His comments came days after American pharmaceutical giant Pfizer and its German partner BioNTech announced that their vaccine had proven 90 percent effective in preventing Covid-19 infections in ongoing Phase 3 trials involving more than 40,000 people. The companies said they expect to supply up to 50 million vaccine doses globally in 2020, and up to 1.3 billion doses in 2021. However, Pfizer's vaccine must be stored at -70 degrees Celsius (-94 degrees Fahrenheit) or else it falls apart, well beyond the capability of most hospital freezers let alone domestic appliances. Rachel Silverman, a policy fellow at the Center for Global Development, has already warned that maintaining the Pfizer vaccine's "ultra-cold chain" from factory to patients' arms constitutes "an enormous logistical challenge even in the West". "Our vaccine will be like the 'flu vaccine, you can keep it in your refrigerator," this avoiding the problem, Bogillot told the CNews channel. "This will be an advantage for some countries," he added. The Sanofi vaccine, one of many in development, will be available for distribution next June, Bogillot added. The results of the Phase 2 tests, involving hundreds of people, will be made public in early December, he added. If those results are positive then Phase 3 trials involving thousands of people will begin, alongside mass production. Eleven of the vaccines under development have already begun Phase 3 trials. The Pfizer vaccine is "a little more advanced" in the development process, said Bogillot, but "one laboratory is not going to be able to supply the doses for the whole planet. "We will need to have several winners at the end of this race." The Sanofi product will also be made avaiable at an "affordable" price he said, without giving details. tsz/aue/pvh/cdw
schema:headline	Sanofi says its vaccine won't need supercooling
schema:mentions	Fahrenheit CNews Refrigerator Rachel Green Medication Planet Influenza France Pfizer Vaccine United States Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Supercooling Aue Sanofi CDW PVH (company)
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-11-15 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	77 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software